NGNE: חוב לטווח קצר של החברה Neurogene

This price chart on GURU.Markets illustrates the price action of Neurogene Inc. (NGNE), where the specific short-term debt metric stands at 0.01. This biotech player focuses on developing gene therapies for children with rare brain pathologies, planning future profits from the implementation of new drugs. Meanwhile, the business operates within a stable US legal climate, remaining shielded from global trade conflicts due to the humanitarian status of medicine.

This metric aggregates all obligations of Neurogene Inc. (NGNE) due for repayment within twelve months. This metric determines the company's ability to service loans without compromising operational activities. For a biopharmaceutical startup, such loans often fund the costly development of viral vectors. Liquidity assessment is critical given high R&D expenditures. By analyzing the short-term debt trend, an investor evaluates the financial stability of the gene therapy business.